Hep C Quickly Fades with an Oral Investigational Drug Combo
A small Japanese study shows a quick and lasting response to an interferon-free regimen of Daclatasvir and Asunaprevir.
Continue reading »Research & Treatment News
Share
Follow Us
Hep C Trial Reports Good Results for Alisporivir
Representing a new type of Hepatitis C drug, the debut of Alisporivir (a cyclophilin inhibitor) delivers encouraging news for interferon-free Hepatitis C treatment.
Continue reading »MitoQ Could Benefit Chronic Hepatitis Patients
Nov 18, 2011
1 Comment
Antioxidants are typically advised for people with chronic hepatitis, but MitoQ takes this idea to an even greater therapeutic level.
Continue reading »Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments
Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.
Continue reading »Promacta Could Ease Hepatitis C Treatment Complications
Depending on the results of a study investigating Promacta for Hepatitis C blood-related treatment complications, this medication could become a valued addition to managing the side effects of Hepatitis C combination therapy.
Continue reading »Drug Thwarts Hep C Return in Transplanted Livers
In a phase 2 study, infusions of MassBiologic's human monoclonal antibody suppressed Hepatitis C resurgence in liver transplant recipients.
Continue reading »Johns Hopkins University – Upcoming Hep C Clinical Studies & Enrollments
Patient recruitment for clinical trials - October 2011
Continue reading »HCV Previous Non-Responders Have Twice the Viral Clearance with TMC435
At the conclusion of a Phase IIb study, adding Medivir's TMC435 to ribavirin and pegylated interferon more than doubled the success rate for Hepatitis C previous non-responders.
Continue reading »No Interferon in Phase 3 Trials of Hep C Drug PSI-7977
Based on previous encouraging results, Pharmasett's PSI-7977 will begin Phase 3 testing in three distinct Hepatitis C trials - all without interferon.
Continue reading »Vertex Launching 3-Month Study of Incivek
Hoping to show its ability to cure Hepatitis C in a shorter period of time, Incivek will be evaluated for its effectiveness in just 12 weeks.
Continue reading »
